NEW YORK, NY / ACCESSWIRE / January 23, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
SPPI Shareholders Click Here: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-lawsuit-submission-form?prid=35852&wire=1
VERU Shareholders Click Here: https://www.zlk.com/pslra-1/veru-lawsuit-loss-submission-form?prid=35852&wire=1
YMAB Shareholders Click Here: https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=35852&wire=1
* ADDITIONAL INFORMATION BELOW *
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
This lawsuit is on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. common stock during the period December 6, 2021 through September 22, 2022, inclusive.
Lead Plaintiff Deadline : February 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-lawsuit-submission-form?prid=35852&wire=1
According to the filed complaint, defendants were conducting a phase 2 clinical trial called ZENITH20, which was an ongoing, multicenter, multi-cohort, open-label, activity-estimating study evaluating the anti-tumor effects, safety, and tolerability of poziotinib in patients with locally advanced or metastatic non-small cell lung cancer that have certain mutations and were previously treated with the standard of care. Although defendants represented that the safety and efficacy data from the ZENITH20 trial were positive and that they had initiated a required confirmatory phase 3 study, on September 20, 2022, a briefing document from the United States Food and Drug Administration Oncologic Drugs Advisory Committee disclosed not only negative data on the safety and efficacy of poziotinib, but also a failure by the Company to enroll any patients in a required phase 3 confirmatory trial.
Veru Inc. (NASDAQ:VERU)
This lawsuit is on behalf of all investors who purchased or otherwise acquired Veru Inc. common stock between May 11, 2022 and November 9, 2022, inclusive.
Lead Plaintiff Deadline : February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/veru-lawsuit-loss-submission-form?prid=35852&wire=1
According to the filed complaint, 1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company's interactions with the United States Food and Drug Administration; 2) defendants misled Veru's shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization ('EUA') and even the submission of a New Drug Application without any further studies; and 3) the Company's filings concealed the true risks faced by Veru in gaining approval for its EUA request.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
This lawsuit is on behalf of persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. common stock on the open market or pursuant to registration statements filed with the U.S. Securities and Exchange Commission during the period October 6, 2020 through October 28, 2022, inclusive.
Lead Plaintiff Deadline : March 20, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=35852&wire=1
According to the filed complaint, (i) Y-mAbs misrepresented the U.S. Food and Drug Administration's ('FDA') willingness to approve omburtamab, the Company's lead product candidate, for marketing based on the existing clinical trials; (ii) the Company misrepresented that progress was being made that would align with the FDA's requirements to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies; (iii) the FDA had repeatedly advised Y-mAbs that it was unlikely to grant approval for the marketing of omburtamab; and (iv) Y-mAbs had elected to submit the March 31, 2022 Biologics License Application prior to reaching agreement with the FDA on the content of the application.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE : Levi & Korsinsky, LLP
View source version on accesswire.com: